Skip to main content
Delfa

← All trials/NCT03182231

UnknownPhase 1, PHASE2

GLP1-imaging Before and After Bariatric Surgery

Visualizing Beta Cells in Patients With T2D Before and After Bariatric Surgery

Asset

Exenatide

GLP-1 agonist

Listed sites

2

Recruiting sites

2

Estimated enrollment

12

Study population

Bariatric Surgery, Obesity / overweight, Type 2 diabetes

Eligibility highlights

•Female

Primary endpoint

•Pancreatic uptake of 68Ga-NODAGA-exendin-4

Registered trial locations

Locations reported to ClinicalTrials.gov for this trial snapshot. Site count is not enrollment count; per-site enrollment is not available from source.

Identifiers

Registered as

NCT IDNCT03182231
Org study IDNL51980.091.15

Timeline

Milestones

Study start2016-10-07actual
Study first posted2017-06-09actual
Last update posted2022-06-21actual
Primary completion2023-07-01estimated
Study completion2023-07-01estimated

Assets

Investigational agents

Exenatide

Who this study enrolls

Bariatric SurgeryObesity / overweightType 2 diabetes

Who can enroll

Minimum age18 Years
SexFemale
Healthy volunteersNot accepted

Inclusion criteria

•Morbid obese T2D patient who will have RYGB at the Rijnstate in Arnhem
•Female
•Signed informed consent

Mild T2D:

•C-peptide > 1.0 nmol/L
•Only metformin usage as anti-diabetic medication

Progressive T2D:

•C-peptide < 1.0 nmol/L
•Insulin and/or sulfonylurea (SU) usage

Exclusion criteria

•Fasting glucose < 6 at time C-peptide was determined
•Liver failure
•BMI > 50 kg/m-2
•Previous treatment with synthetic exendin
•Pregnancy
•Breast feeding
•Kidney failure
•Age < 18 years
•No signed informed consent

Endpoints (3)

What's being measured

Protocol endpoints and posted registry outcome measures, grouped into outcome categories. Composite endpoints show their component event types. Standard codes (LOINC, SNOMED CT) are shown where available.

Coverage by outcome category

Other (unclassified)
2
Glycemic / diabetes
1

Glycemic / diabetes

1 endpoint
Secondary/protocol endpoint/low confidence

Beta cell function

Time frame:4 years

descriptive

Other (unclassified)

2 endpoints
Primary/protocol endpoint/low confidence

Pancreatic uptake of 68Ga-NODAGA-exendin-4

Time frame:4 years

change from baseline, descriptive

Secondary/protocol endpoint/low confidence

T2D outcome

Time frame:after 1 year

descriptive

Provenance

Sources

Trial identity, design, statusClinicalTrials.gov API v2
Snapshot dateJuly 6, 2026
Endpoint classificationDelfa endpoint taxonomy v2 (May 13, 2026)
Results tableno registry results posted yet

Trial facts come from public ClinicalTrials.gov records. Endpoint categories are Delfa's classification of those records, not a ClinicalTrials.gov field. All figures reflect the July 6, 2026 snapshot.